BMRN · CIK 1048477
What BioMarin Pharmaceutical Inc. told the SEC could break it.
BioMarin's risks are concentrated at both ends of its business. On the demand side three customers each made up at least 10% of net product revenue in 2025 — 14%, 12% and 11%, together 37% — so losing any one would materially hurt results. On the supply side it relies on sole- or single-source suppliers for many critical raw materials and, for certain steps, a single contract manufacturer, while its Galli Drive plant in Novato, California is its only facility for several products (ALDURAZYME, NAGLAZYME, VOXZOGO, PALYNZIQ) and sits near earthquake fault zones. Trade and pricing policy add to this: because it manufactures and packages in Ireland, its U.S. imports are exposed to a Section 232 pharmaceutical-tariff probe, and reimbursement faces pressure from IRA Medicare price negotiation and the EU's HTA regulation.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- pharmaceutical import tariffs (Section 232 national-security probe; Ireland manufacturing)medium
The US Commerce Department is investigating whether foreign-manufactured pharmaceutical ingredients/finished drug product pose a national-security risk warranting additional tariffs; because BioMarin manufactures/packages in Ireland and uses contract manufacturers worldwide, importing its products into the US is tariff-exposed, and pharma supply chains are slow/costly to re-route.
“Since we conduct manufacturing and packaging operations in Ireland for certain of our products and also engage contract manufacturers around the world, the import of our products into the United States is subject to tariffs.”
SEC filing →As of 2026 - IRA Medicare drug-price negotiation, PPACA, EU HTA pricing pressuremedium
Drug-pricing reform pressures BioMarin's reimbursement — the IRA requires HHS to negotiate Medicare Part B/D prices for selected single-source drugs (biologics eligible after 11 years) at a capped ceiling, the IRA's Part D manufacturer-discount program began 2025, and the EU HTA regulation (in force Jan 2025) has added EU pricing pressure.
“The IRA also requires the U.S. Department of Health and Human Services (HHS) to negotiate the selling price of a statutorily specified number of drugs and biologics each year that the CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price.”
Customer concentration
- three customers (A/B/C) each ≥10% of net product revenue (37% combined, unnamed)high
BioMarin's product revenue is concentrated in three (unnamed) customers — Customer A 14%, Customer B 12%, Customer C 11% — together 37% of net product revenues in 2025; loss of any could materially affect results.
“Years Ended December 31, 2025 2024 2023 Customer A 14 % 13 % 14 % Customer B 12 % 12 % 12 % Customer C 11 % 10 % 10 % Total 37 % 35 % 36 %”
SEC filing →As of 2026
Sole-source dependency
- sole/single-source raw-material suppliers and single-facility manufacturing (Novato, earthquake-zone)high
BioMarin relies on sole-source/single-source suppliers for many critical raw materials and, for certain manufacturing steps, a single approved contract manufacturer; its Galli Drive (Novato, CA) plant — the only facility for ALDURAZYME, NAGLAZYME, VOXZOGO and PALYNZIQ — sits near earthquake fault zones, concentrating supply and disaster risk.
“Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for ALDURAZYME, NAGLAZYME, VOXZOGO and PALYNZIQ and is one of two manufacturing facilities for VIMIZIM. This facility is located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Beginning July 1, 2022, pursuant to the 2021 Amendment, the BioMarin Parties were eligible to receive royalties of 4% in the U.S. and 5% outside the U.S. of net sales of Products covered by a Licensed Patent on a product-by-product and country-by-country basis.”
Cited →Catalyst Pharmaceuticals, Inc.
“Under the License Agreement, we pay royalties to the third-party licensor of the rights sublicensed to us from the approval of FIRDAPSE® equal to 7% of net sales (as defined in the License Agreement between BioMarin and the third-party licensor)”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch